A person diagnosed with cancer and her/his family and friends are likely to be highly traumatised with the diagnosis and hectically seeking appropriate, effective and affordable treatment. Western Range Biopharmaceuticals is developing autologous cellular therapy for treatment of cancer and auto-immune diseases. The Cellular Immunotherapies complement existing approach focused on chemotherapy, surgery, and radiotherapy, and focus on difficult cancers (pancreatic, brain) as well as women’s recurrent cancers.

Western Range Biopharmaceuticals’ technologies are related to the cellular immunotherapies for personalized cancer treatment of late-stage metastatic cancer patients. It is currently supplying two indigenously-developed cancer technologies that are both highly effective and affordable.

The first, TheraVacDC+ is a cellular immunotherapy treatment, which is based on training immune cells to fight cancer from within, complements existing treatment modalities like radiation, chemotherapy and surgery. The other is Onco-D-Sens, which helps identify chemotherapy drugs that have the highest efficacy for a particular patient. Many cancer patients, especially relapsed patients are often resistant to many chemotherapy drugs. The current practice to overcome this resistance uses a trial-and-error approach which may take about five to six months while the patient continues to deteriorate. WRB's testing allows screening of selected potential drugs using proprietary 3D culture technology to identify the most efficacious medicines in less than two weeks.

Western Range Biopharmaceuticals targeted cancer therapy will significantly reduce the costs for treatment of cancer and will accelerate the pace of diagnosis and decision on appropriate treatment The increase the 5 year survival rates of patients and in the overall reduction in the survival rates of Indians in their prime and in the most productive group (Currently in India, the 30-69 age groups accounted for about 71% of the deaths). WRB’s offerings are more affordable than those offered by other organisations offering similar treatment modalities in India, USA, European Union, Australia and Germany.

Social Impact:

• Technology platforms will provide tangible benefits to the patients & cancer hospitals
• 3D cytotoxic assays can be used to determine chemo-sensitivity or chemo-resistance of existing drugs
• Plan to develop portfolio of cancer technologies for broader relationship with cancer hospitals